A new prostate cancer treatment could mean men suffer fewer side effects, scientists say. Trials will examine whether aquablation – a therapy using robotics, AI and real-time imaging – works as well ...

The treatment, a type of immunotherapy which harnesses the body’s immune system to fight cancer, was found to shrink tumours ...

For many men with prostate cancer, weeks of daily treatments are no longer the norm. Jonathan Tward, MD, a radiation oncologist at Huntsman Cancer Institute, explains how image guidance, real-time ...

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have validated a test that can accurately predict which patients with prostate cancer are at higher risk of developing long-lasting ...

A DRUG that shrinks tumours in patients with untreatable prostate cancer has shown “remarkable” results, scientists have said. The treatment, called VIR-5500, harnesses the body’s ...

As part of its Speaking Out video series, CURE talked to Dr. Brian Keith McNeil, on behalf of ZERO Prostate Cancer, about managing side effects following prostate cancer treatment. While treatment ...

Learn how Huntsman Cancer Institute uses cutting‑edge diagnostics and personalized care to treat early‑stage prostate cancer.

Men with advanced prostate cancer undergoing local therapies such as radiation therapy or radical prostatectomy experience significantly more gastrointestinal and sexual issues, along with problems ...

Daily scans taken during prostate cancer radiotherapy could be repurposed to guide changes to treatment, reducing the risk of side effects, a study suggests. Using AI, scientists found that images ...

PROSTOX test predicts urinary side effects in prostate cancer patients using microRNAs to assess genetic risk factors. The test identifies high-risk patients, who are 10 to 12 times more likely to ...

For patients with intermediate-risk, localized prostate cancer, radiation therapy delivered in five sessions reduced patient-reported side effects compared to longer courses of radiation, according to ...

The new drug, known as VIR-5500, uses a so-called cloaking device and only activates when it reaches the tumour ...